Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This medicine is generally administered once daily with the evening meal.
The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg.
Patients who have not previously received drug treatment for diabetes and for whom adequate glycemic control is difficult to achieve with monotherapy:
When used as initial therapy in patients who have not previously received drug treatment for diabetes, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily.
The dose should be adjusted gradually to reduce gastrointestinal adverse reactions to metformin.
In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin previously taken or an appropriately titrated dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate.
In patients switching to this medicine from combination therapy with dapagliflozin and metformin, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate.
When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia.
The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other glucose-lowering agents. Because any change may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made with careful monitoring.
This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet.
Renal impairment
No dosage adjustment is necessary in patients with mild renal impairment.
In patients with an estimated glomerular filtration rate (eGFR) of ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2, without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medicine is not recommended in patients with an eGFR < 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) decreases to < 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.
Older adults
Because metformin is excreted through the kidneys and renal function tends to decline in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).
Improvement of glycemic control in adults with type 2 diabetes mellitus
Type 2 diabetes
blood glucose control disorders
cardiovascular diseases
cardiovascular risk factors.
View approved original textHide original text
This medication is used to improve blood glucose control in adult patients with type 2 diabetes when dapagliflozin and metformin are administered together. It is used as an adjunct to dietary and exercise therapy, particularly in patients who do not have sufficient blood glucose control. In addition, the effects of dapagliflozin on the occurrence of cardiovascular events should be carefully monitored in type 2 diabetes patients with cardiovascular disease or risk factors. Please consult professional information before use to ensure safe usage. This medication effectively improves blood glucose control in diabetic patients.
How to take
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This medicine is generally administered once daily with the evening meal.
The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg.
Patients who have not previously received drug treatment for diabetes and for whom adequate glycemic control is difficult to achieve with monotherapy:
When used as initial therapy in patients who have not previously received drug treatment for diabetes, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily.
The dose should be adjusted gradually to reduce gastrointestinal adverse reactions to metformin.
In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin previously taken or an appropriately titrated dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate.
In patients switching to this medicine from combination therapy with dapagliflozin and metformin, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate.
When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia.
The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other glucose-lowering agents. Because any change may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made with careful monitoring.
This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet.
Renal impairment
No dosage adjustment is necessary in patients with mild renal impairment.
In patients with an estimated glomerular filtration rate (eGFR) of ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2, without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medicine is not recommended in patients with an eGFR < 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) decreases to < 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.
Older adults
Because metformin is excreted through the kidneys and renal function tends to decline in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).
Precautions
This medication is used for diabetes treatment and contains metformin and dapagliflozin.
This medication should not be used in patients with poor kidney function or certain heart diseases and liver dysfunction.
Before administration, kidney function and fluid status must be confirmed, and caution is especially needed in elderly patients or those with dehydration.
Hypoglycemic symptoms may occur during treatment; therefore, dosage adjustments may be necessary when taken with insulin or other blood glucose-lowering agents.
Lactic acidosis, a rare side effect, can be life-threatening, so if symptoms such as fatigue, muscle pain, or shortness of breath occur, immediate consultation with medical personnel is required.
The risk of genital and urinary tract infections may increase, so prompt treatment should be sought if infection symptoms arise.
Pregnant or breastfeeding women should not use this medication; if planning to become pregnant, consult a physician.
The risk of side effects may increase when taking this medication with alcohol, so excessive drinking should be avoided.
In cases of overdose, immediate medical attention is necessary; dialysis may be required.
The safety and efficacy of this medication in children have not been established, so it should not be used in children.
Regular monitoring of kidney function and serum vitamin B12 levels is recommended during treatment.
Caution is required when driving or operating machinery as dizziness may occur.
Side effects
severe lactic acidosis
severe hypoglycemia
vulvitis
balanitis
genital infection
urinary tract infection
fungal infection
hypoglycemia
decreased fluid volume
thirst
Show 85 moreCollapse
diabetic ketoacidosis
dizziness
constipation
dry mouth
low back pain
dysuria
polyuria
nocturia
vulvar itching
genital itching
increased hematocrit
decreased renal creatinine clearance
dyslipidemia
elevated blood creatinine
elevated blood urea
weight loss
ketoacidosis
urosepsis
pyelonephritis
acute kidney injury
renal dysfunction
rash
diarrhea
nausea
vomiting
decreased vitamin B12
Guillain-Barré syndrome
bacterial pneumonia
sialadenitis
tendinitis
chest pain
thermal burn
wrist fracture
gastrointestinal stromal tumor
malignant lung neoplasm
uterine fibroids
atrial fibrillation
acute cholecystitis
epigastric pain
dyspepsia
abdominal discomfort
abdominal pain
gastric ulcer
irritable bowel syndrome
salivary gland mass
toothache
headache
facial paralysis
peripheral neuropathy
sensory abnormalities
drowsiness
tremor
nasopharyngitis
pharyngitis
adenoviral conjunctivitis
herpes zoster
pneumonia
rhinitis
elevated alanine aminotransferase
increased blood glucose
arthralgia
myalgia
fibromyalgia syndrome
osteoarthritis
osteochondritis
limb pain
periarticular inflammation
tendinosis
trigger finger
weakness
fatigue
peripheral edema
edema
pain
vitamin D deficiency
hyperglycemia
urethral syndrome
cough
hyperventilation
skin abrasion
itching
palpitations
insomnia
type 2a hyperlipidemia
sensorineural hearing loss
Not everyone experiences these, and they can vary from person to person.
Storage
This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is recommended to maintain storage temperature between 1 degree and 30 degrees Celsius to safely preserve the effectiveness of the medication.
Appearance and packaging
Appearance
Orange, biconvex, oval film-coated tablet.
Package unit
30 tablets/bottle
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.